Онколитические вирусы в терапии злокачественных новообразований
https://doi.org/10.17650/1726-9784-2018-17-4-6-19
Аннотация
В обзоре охарактеризованы основные типы онколитических вирусов, рассмотрены механизмы их действия на опухолевую клетку. Приведены примеры оптимизации вирусного генома с целью усиления онколитических свойств вируса. Описаны достижения в области создания противоопухолевых средств на основе онколитических вирусов и способы их применения в онкологии.
Об авторах
Н. К. Клаан
ФГБУ «Всероссийский институт научной и технической информации»
Россия
Россия
125190 Москва, А-190, ул. Усиевича, 20
Наталья Константиновна Клаан
Л. П. Акиньшина
ФГБУ «Всероссийский институт научной и технической информации»
Россия
125190 Москва, А-190, ул. Усиевича, 20
Россия
125190 Москва, А-190, ул. Усиевича, 20
Т. А. Пронина
ФГБУ «Всероссийский институт научной и технической информации»
Россия
125190 Москва, А-190, ул. Усиевича, 20
Россия
125190 Москва, А-190, ул. Усиевича, 20
Список литературы
1. Russell S.J., Peng K.W., Bell J.C. Oncolytic virotherapy. Nat Biotechnol 2012; 30:658–70. DOI:10.1038/nbt. 2287.
2. Святченко В.А., Тарасова М.В., Нетесов С.В. и др. Онколитические аденовирусы в терапии злокачественных новообразований: современное состояние и перспективы. Молекулярная биология 2012;46(4):556–69. [Sviatchenko V.A., Tarasova M.V., Netesov S.V., Chumakov P.M. Oncolytic adenoviruses in anti-cancer therapy: current status and perspectives. Molekulyarnaya biologiya = Molecular Biology 2012;46(4):556–69 (In Russ.)].
3. Кочнева Г.В., Сиволобова Г.Ф., Юдина К.В. и др. Онколитические поксвирусы. Молекулярная генетика, микробиология и вирусология 2012;1:8–15. [Kochneva G.V., Sivolobova G.F., Iudina K.V. et al. Oncolytic poxviruses. Molekuliarnaia genetika, mikrobiologiia i virusologiia = Molecular Genetics, Microbiology and Virology 2012;1:8–15 (In Russ.)].
4. Матвеева О.В., Кочнева Г.В., Нетесов С.В. и др. Механизмы онколитического действия парамиксовируса Сендай. Acta Naturae 2015;7(2):6–17. [Matveeva O.V., Kochneva G.V., Netesov S.V., et al. Mechanisms of oncolysis by paramyxovirus Sendai. Acta Naturae 2015;7(2):6–16 (In Russ.)].
5. Баклаушев В.П., Горяйнов С.А., Потапов А.А. и др. Онколитические вирусы в лечении низкодифференцированных глиом. Клиническая практика 2015;2:46–59. [Baklaushev V.P., Goryainov S.A., Pavlova G.V. et al. Oncolytic viruses in high-grade gliomas treatment. Klinicheskaia praktika = Klinical praktike 2015;2:46–59 (In Russ.)].
6. Donina S., Strēle I., Proboka G. et al. Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study. Melanoma Res 2015;25(5):421–26. DOI: 10.1097/CMR.0000000000000180. PMID: 26193376.
7. Ring C.J. Cytolytic viruses as potential anti-cancer agents. Gen Virol 2002;83:491–502. DOI: 10.1099/0022-1317-83-3-491. PMID: 11842243.
8. de Pace N.G. Sulla scomparsa di un enorme cancro vegetante del collo dell utero senza cura chirurgica. Ginecologia 1912;9:82–8.
9. Приедите И.Ю., Гарклава P.P., Муцениеце А.Я. Лечение больных раком желудка после паллиативных операций. Материалы III конференции онкологов ЭССР, ЛитССР и ЛатвССР. Рига, 1971. 77 с. [Priedite I.Yu., Garklava R.R., Mutsienitsene A.Ya. Treatment of patients with gastric cancer after palliative operations. Proceedings of the III Conference of Oncologists of the ESSR, the Lithuanian SSR and the Latvian SSR. Riga, 1971. 77 p. (In Russ.)].
10. Муцениеце А.Я. Онкотропизм вирусов и проблема виротерапии злокачественных опухолей. Рига: Зинатне, 1972. 442 с. [Mutsienitsene A.Ya. Oncotropism of viruses and the problem of virotherapy of malignant tumors. Riga: Zinatne, 1972. 442 p. (In Russ.)].
11. Муцениеце А.Я., Фердат А.К. Феномен усиления иммуногенности опухолевых клеток вирусами. Вирусы в терапии опухолей. Рига: Зинатне, 1978. С. 5–34. [Mutsienitsene A.Ya., Ferdat A.K. The phenomenon of increased immunogenicity of tumor cells by viruses. Viruses in the treatment of tumors. Riga: Zinatne,1978. P. 5–34 (In Russ.)].
12. Моисеенко В.М., Балдуева И.А., Хансон К.П. Вакцинотерапия злокачественных опухолей. Вопросы онкологии 1999;45(3):327–32. [Moiseenko V.M., Baldueva I.A., Khanson K.P. Vaccination therapy for malignant tumors. Voprosy onkologii = Problems of Onkology 1999;45(3):327–32 (In Russ.)].
13. Voroshilova M.K. Potential use of nonpathogenic enteroviruses for control of human disease. Prog.Med. Virol. 1989;36:191–202. PMID: 2555836.
14. Martuza R., Malick A., Markert J. et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991;252:854–6. DOI:10.1126/science.1851332. PMID: 1851332.
15. Pesonen S., Nokisalmi P., Escutenaire S. et al. Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2LD24 in patients with metastatic and refractory solid tumors. Gene Ther 2010;17:892–904. DOI: 10.1038/gt.2010.17. PMID: 20237509.
16. Калинин В.Л. Введение в молекулярную вирусологию. СПб.: СПбГТУ, 2002.120 с. [Kalinin V.L. Introduction to molecular virology. SPb.: SPbSTU, 2002.120 р. (In Russ.)]. Graham F.L., Prevec L. Manipulation of adenovirus vectors. Methods in Molecular Biology 1991;7:109–28. DOI: 10.1385/0-89603-178-0:109.
17. Garber K. China approves world’s first oncolytic virus therapy for cancer treatment. J Nat Canc Inst 2006;98:298–300. DOI: 10.1093/jnci/djj111. PMID: 16507823.
18. Bischoff J.R., Kirn D.H., Williams A. et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996;274:373–6. DOI:10.1126/science. 274.5286.373. PMID: 8832876.
19. Shirakawa T. The current status of adenovirus-based cancer gene therapy. Mol Cells 2008;25(4):462–6. PMID: 18460898.
20. Hanna E., Quick J., Libutti S.K. The tumour microenvironment: a novel target for cancer therapy. Oral Dis 2009;15:8–17. DOI: 10.1111/j.1601-0825.2008.01471.x. PMID: 18992016.
21. Cerullo V., Pesonen S., Diaconuet I. et al. Oncolytic adenovirus coding for granulocyte macrophage colonystimulating factor induces antitumoral immunity in cancer patients. Canc Res 2010;70:4297–309. DOI: 10.1158/0008-5472.CAN-09-3567. PMID: 20484030.
22. Kosaka T., Davydova J., Ono H.A. et al. Imaging and antitumoral effect of a cyclo-oxygenase 2-specific replicative adenovirus for small metastatic gastric cancer lesions. Anticancer Res 2015;35:5201–10. PMID: 26408678.
23. Hardcastle J., Kurozumi K., Dmitrieva N. et al. Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1. Mol Ther 2010;18:285–94. DOI: 10.1038/mt.2009.232. PMID: 19844198.
24. Manservigi R., Argnani R., Marconi P. HSV recombinant vectors for gene therapy. Open Virol J 2010;4:123–56. DOI: 10.2174/1874357901004030123. PMID: 20835362.
25. Reid V., Yu Z., Schuman T. et al. Herpes oncolytic therapy of salivary gland carcinomas. Int J Canc 2008;122:202–8. DOI: 10.1002/ijc. 23030. PMID: 17764117.
26. Aghi M., Martuza R.L. Oncolytic viral therapies – the clinical experience. Oncogene 2005;24:7802–16. DOI: 10.1038/sj. onc. 1209037. PMID: 16299539.
27. Currier M.A., Gillespie R.A., Sawtell N.M. et al. Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide. Mol Ther 2008;16:879–85. DOI: 10.1038/mt.2008.49. PMID: 18388918.
28. Thorne S.H., Tae-Ho H. Hwang, O’Gorman W.E. et al. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J Clin Invest 2007;117:3350–8. DOI: 10.1172/JCI32727. PMID: 17965776.
29. Lee J., Roh M., Lee Y. et al. Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM–CSF following intravenous administration in a rabbit tumor model. Canc Gene Ther 2010;17:73–9. DOI: 10.1038/cgt.2009.50. PMID: 19629143.
30. Зонов Е.В., Кочнева Г.В., Тупицина А.В., Рябчикова Е.И. Противоопухолевый эффект апоптин-продуцирующего рекомбинантного штамма вируса осповакцины in vivo связан с блокированием митотического деления опухолевых клеток. Молекулярная генетика, микробиология и вирусология 2016;34(4):154–9. [Zonov E.V., Tupitsyna A.V., Ryabchikova E.I., Kochneva G.V. The in vivo antitumor effect of the apoptin-producing recombinant vaccinia virus strain is associated with blockage of mitotic division of cancer cells. Molekuliarnaia genetika, mikrobiologiia i virusologiia = Molecular Genetics, Microbiology and Virology 2016;34(4):154–9 (In Russ.)].
31. Tattersall P. The evolution of parvoviral taxonomy. In The parvoviruses. London: Hodder Arnold, 2006. Pp. 5–14.
32. Maxwell I.H., Terrell K.L., Maxwell F. Autonomous parvovirus vectors. Methods 2002;28(2):168–81. DOI:10.1016/s1046-2023(02)00221-9. PMID: 12413415.
33. Cornelis J.J., Deleu L., Koch U. et al. Parvovirus oncosuppression in “The parvoviruses”. London: Hodder Arnold, 2006. P. 365–84. DOI:10.1201/b13393-31.
34. Moehler M.H., Zeidler M., Wilsberg V. et al. Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells. Hum Gene Ther 2005;16(8):996–1005. DOI: 10.1089/hum.2005.16.996. PMID: 16076257.
35. Rommelaere J., Geletneky K., Angelova A.L. et al. Oncolytic parvoviruses as cancer therapeutics. Cytokine Growth Factor Rev 2010;21(2–3):185–95. DOI: 10.1016/j.cytogfr.2010.02.011. PMID: 20211577.
36. Bhat R., Dempe S., Dinsart C. et al. Enhancement of NK cell antitumor responces using an oncolytic parvovirus. Int J Cancer 2011;128:908–19. DOI: 10.1002/ijc.25415. PMID: 20473905.
37. Geletneky K., Herrero Y.C. M., Rommelaere J. et al. Oncolytic potential of rodent parvoviruses for cancer therapy in humans: a brief review. J Vet Med 2005;52:327–30. DOI: 10.1111/j.1439-0450.2005.00877.x. PMID: 16316394.
38. Hashiro G., Loh P.C., Yau J.T. The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch Virol 1977;54(4):307–15. DOI:10.1007/bf01314776. PMID: 562142.
39. Coffey M.C., Strong J.E., Forsyth P.A. et al. Reovirus therapy of tumors with activated Ras pathway. Science 1998;282:1332–4. DOI:10.1126/science. 282.5392.1332. PMID: 9812900.
40. Clarke P., Tyler K.L. Down-regulation of cFLIP following reovirus infection sensitizes human ovarian cancer cells to TRAIL-induced apoptosis. Apoptosis 2007;12:211–23. DOI: 10.1007/s10495-006-0528-4. PMID: 17136319.
41. Kilani R.T., Tamimi Y., Hanel E.G. et al. Selective reovirus killing of bladder cancer in a coculture spheroid model. Virus Res 2003;93(1):1–12. DOI:10.1016/s0168-1702(03)00045-5. PMID: 12727337.
42. Samson A., Bentham M., Scott K. et al. Oncolytic reovirus as a combimed antiviral and antitumor agent for the treatment of liver cancer. Gut 2018;67(3):562–73. DOI: 10.1136/gutjnl-2016-312009. PMID: 27902444.
43. Thirukkumaran C.M., Nodwell M.J., Hirasawa K., et al. Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic. Cancer Res 2010;70(6):2435–44. DOI: 10.1158/0008-5472.CAN-09-240. PMID: 20215509.
44. Suskind R.G., Huebner R.J., Rowe W.P. et al. Viral agents oncolytic for human tumors in heterologous host. OncoLytic effect of Coxsackie B viruses. Proc Soc Biol Med 1957;94:309–18. DOI:10.3181/00379727-94-22931. PMID: 13408245.
45. Ворошилова М.К., Ваганова Н.Т. Опыт лечения больных опухолями желудочно-кишечного тракта живыми энтеровирусными вакцинами. Материалы симпозиума по вирусному онколизу и искусственной гетерогенизации опухолей. 1969. [Voroshilov M.K., Vaganova N.T. Experience in treating patients with gastrointestinal tumors with live enterovirus vaccines. Materials of the Symposium on Viral Oncolysis and Artificial Heterogenization of Tumors 1969. (In Russ.)].
46. Goetz C., Gromeier M. Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiforme. Cytokine Growth Factor Rev 2010;21:197–203. DOI: 10.1016/j.cytogfr.2010.02.005. PMID: 20299272.
47. Shafren D.R., Sylvester D., Johansson E. et al. Oncolysis of human ovarian cancers by Echovirus Type 1. Int J Cancer 2005;115:320–8. DOI: 10.1002/ijc.20866. PMID: 15688406.
48. Муцениеце А.Я., Фелдмане Г.Я., Шаповалова Е.А. и др. Биотерапия иммуномодуляторами вирусной природы RIGVIR и LARIFANS для профилактики прогрессии злокачественных опухолей: клинический опыт с 1968. Российский биотерапевтический журнал 2007;6(1):61. [Mutsienitsene A.Ya., Feldmane G.Ya., Shapovalova E.A. Biotherapy of viral immunomodulators RIGVIR and LARIFANS for the prevention of progression of malignant tumors: clinical experience since 1968. Rossiysky Bioterapevtichesky Zhurnal = Russian Biotherapeutic Journal 2007;6(1):61. (In Russ.)].
49. Haley E.S., Au G.G., Carlton B.R. et al. Regional administration of oncolytic echovirus 1 as a novel therapy for the peritoneal dissemination of gastric cancer. J Mol Med 2009;87:385–99. DOI: 10.1007/s00109-008-0433-0. PMID: 19139835.
50. Toyoda H., Yin J., Mueller S. et al. Oncolytic treatment and cure of neuroblastoma by a novel attenuated poliovirus in a novel poliovirus-susceptible animal model. Cancer Res 2007;67:2857–64. DOI: 10.1158/0008–5472.CAN-06-3713. PMID: 17363609.
51. Gromeier M., Lachmann S., Rosenfeld M.R. et al. Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc Natl Acad Sci. USA 2000;97:6803–8. PMID: 10841575.
52. Zamarin D., Palese P. Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol 2012;7:347–67. DOI: 10.2217/fmb.12.4. PMID: 22393889.
53. Lorence R., Reichard K., Katubig B. et al. Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle desease virus therapy. J Nat Canc Inst 1994;86(16):1228–34. DOI:10.1093/jnci/86.16.1228. PMID: 8040891.
54. Galanis E. Therapeutic potential of oncolytic measles virus: promises and challenges. Clin Pharmacol Ther 2010;88:620–5. DOI: 10.1038/clpt.2010.211. PMID: 20881957.
55. Peng K.-W., Hadac E.M., Anderson B.D. et al. Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model. Canc Gene Ther 2006;13:732–8. DOI: 10.1038/sj.cgt.7700948. PMID: 16543921.
56. Msaouel P., lankov I. D., Allen C. et al. Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter. Mol Ther 2009;17:2041–8. DOI: 10.1038/mt.2009.218. PMID: 19773744.
57. Altomonte J., Marozin S., Schmid R.M. et al. Engineered Newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma. Mol Ther 2010;18:275–84. DOI: 10.1038/mt.2009.231. PMID: 19809404.
58. Gainey M.D., Manuse M.J., Parks G.D. A hyperfusogenic F protein enhances the oncolytic potency of a paramyxovirus simian virus 5 P/V mutant without compromising sensitivity to type I interferon. J Virol 2008;82:9369–80. DOI: 10.1128/JVI.01054–08. PMID: 18667520.
59. Pap M., Bator J., Szeberenyi J. Sensitivity of human malignant melanoma cell lines to Newcastle disease virus. Anticancer Res 2015;35:5401–6. PMID: 26408702.
60. Матвеева О.В., Кочнева Г.В., Нетесов С.В. и др. Механизмы онколитического действия парамиксовируса Сендай. Acta Naturae 2015;7(2):617. [Matveeva O.V., Kochneva G.V., Netesov S.V. et al. Mechanisms of Oncolysis by Paramyxovirus Sendai. Acta Naturae 2015;7(2):6–16 (In Russ.)].
61. Zeng D., Zang T., Zhow S. et al. Proteomic analysis gastric cancer cells treated with vesicular stomatitis virus matrix protein. Protein J 2011;30:308–17. DOI: 10.1007/s10930-011-9331-3. PMID: 21574062.
62. Kournioti С., Park M.-S., GarciaSastre A. et al. Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer. Cancer Res 2004;64:3265–70. DOI:10.1016/j.ymthe.2004.06.980. PMID: 15126368.
63. Zhang K., Matsui Y., Hadaschik B.A. et al. Down-regulation of type I interferon receptor sensitizes bladder cancer cells to vesicular stomatitis virus-induced cell death. Int J Cancer 2010;127(4):830–8. DOI: 10.1002/ijc.25088. PMID: 19957332.
64. Шлезингер М.Д. Репликация тогавирусов. В кн.: Вирусология. Под ред. Б. Филдса, Д. Найпа. М., 1989. Т. 2. С. 343–366. [Shlezinger M.D. Replication of togaviruses. In: Virology. Ed.B. Fields, D. Nypa. Moscow, 1989. Vol. 2. Pp. 343–66. (In Russ.)].
65. Рогозин Е.А., Уразова Л.Н., Ильинских Н.Н. Влияние вируса венесуэльского энцефаломиелита на жизнеспособность и уровень цитогенетических нарушений в клетках карциномы Эрлиха in vitro. Экспериментальная онкология 1999;21(1): 70–2. [Rogozin E.A., Urazova L.N., Il’inskikh N.N. The effect of Venezuelan encephalomyelitis virus on viability and the level of cytogenetic disorders in Ehrlich carcinoma cells in vitro. Experimentalnaia oncologiia = Experimental oncology 1999;21(1):70–2 (In Russ.)].
66. Рогозин Е.А., Уразова Л.Н., Серебров В.Ю. Изменения цитологических показателей опухоли Эрлиха, индуцированные комплексной терапией винкристином и вакцинным штаммом вируса венесуэльского энцефаломиелита. Сибирский научный медицинский журнал 2003;2:121–4. [Rogozin E.A., Urazova L.N., Serebrov V.Yu. Experimental therapy of Ehrlich carcinoma with vincristine and the vaccine Venezuelan encephalomyelitis virus strain and its cytological evolution. Sibirskiy naushniy medicinskiy journal = Siberian scientific medical journal 2003;2:121–4 (In Russ.)].
67. Громова А.Ю. Противоопухолевые свойства вакцинного штамма вируса венесуэльского энцефаломиелита и его онколизата. Автореф. дис. … канд. биол. наук. СПб., 1999. [Gromova A.Yu. Antitumor properties of the vaccine strain of Venezuelan encephalomyelitis virus and its oncolysate. Abstr. dissertation (Biology). St. Petersburg, 1999 (In Russ.)].
68. Shino Y., Sunouchi K., Asano T. et al. Patent № 7270812 B2, Sep. 18, 2007. Pharmaceutical composition for treatment of cancers.
69. Ito H., Aoki H., Kuhnel F. et al. Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. J Nat Cancer Inst 2006;98:625–36. DOI: 10.1093/jnci/djj161. PMID: 16670388.
70. García M.A., Krupa M., Esteban M. Antitumor activity of oncolytic vaccinia virus expressing the interferon-induced dsRNA dependent protein kinase PKR. An R Acad Nac Farm 2010;76(3):327–42.
71. Mundschau L., Faller D. Oncogenic ras induces an inhibitor of double-strand RNA-dependent eukaryotic initiation factor 2a-kinase activation. J Biol Chem 1992;267:23092–98.
72. Smith K.D., Mezhir J.J., Bickenbach K. et al. Activated MEK suppresses activation PKR and enables efficient replication and in vivo oncolysis by delthagamma(1) 34,5 mutants of herpes simplex virus 1. J Virol 2006;80:1110–20. DOI: 10.1128/JVI.80.3.1110-1120.2006. PMID: 16414988.
73. Корчагина К.В., Губанова Н.В., Максимова Д.А. и др. Морфологическое изучение влияния вируса болезни Ньюкасла штамма ndv/adigeya/duck/8 на ультраструктурную организацию нормальных и опухолевых клеток человека в культуре. Вестник НГУ. Серия Биология, Клиническая медицина 2012;10(2):84–93. [Korchagina K.V., Gubanova N.V., Maksimova D.A. et al. Morphological study of influence of Newcastle disease virus strain ndv/adigeya/duck/8 on ultrastructural organization of normal and cancer cells in vitro. Bulletin of the NSU. Biology Series. Clinicheskaia Medicina = Clinical Medicine 2012;10(2):84–93 (In Russ.)].
74. Volgestein B., Lane D., Levine A.J. Surfing the p53 network. Nature 2000;408:307–10. DOI: 10.1038/35042675. PMID: 11099028.
75. Chen G., Zhang S., He X. et al. Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives. OncoTargets Ther 2014;7:1901–9. DOI: 10.2147/OTT.S50483. PMID: 25364261.
76. Querido E., Blanchette P., Yan Q. et al. Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a cullin-containing complex. Genes Dev 2001;15:3104–17. DOI: 10.1101/gad.926401. PMID: 11731475.
77. Greenblatt M.S., Bennett W.P., Hollstein M. et al. Mutation in the p53 suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855–78. DOI:10.1016/0169-5002(94) 92083–4. PMID: 8069852.
78. Tollefson A.E., Ryerse J.S., Scaria A., et al. The E3–11.6 kDa adenovirus death protein (ADP) is required for efficient cell death: characterization of cells, infected with adp mutants. Virology 1996;220:152–62. DOI: 10.1006/viro.1996.0295. PMID: 8659107.
79. Khuri F.A., Nemunaitis J., Ganly I. et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000;6:879–85. DOI:10.1038/78638. PMID: 10932224.
80. Nemunaitis J., Tong A.W., Nemunaitis M. et al. A phase I study of telomerase – specific replication competent oncolytic adenovirus (telomelysin) for varios solid tumors. Mol Ther 2010;18:429–34. DOI:10.1038/mt.2009.262.
81. Nakagawa T., Tanaka H., Shirakawa T. et al. Cyclooxygenase 2 Promoter – Based Replication-Selective Adenoviral Vector for Hypopharyngeal Cancer. Arch Otolaryngol Head Neck Surg 2009;135(3):282–6. DOI: 10.1001/archoto.2008.549. PMID: 19289707.
82. Shirakawa T. Hamada K., Zhang Z. et al. A COX-2 promoter-based replicationselective adenoviral vector to target COX-2 – expressing human bladder cancer cells. Clin Canc Res 2004;10:4342–8. DOI: 10.1158/1078-0432.CCR-03-0267. PMID: 15240520.
83. Choi J.W., Jung S.J., Kasala D. et al. pH-sensitive oncolytic hybrid targeting acidic tumor microenvironment and angiogenesis. J Conr Release 2015;205: 134–43. DOI: 10.1016/j.jconrel.2015.01.005. PMID: 25575865.
84. Lu Yi., Zang Yu., Chang G. et al. Comparison of prostate specific promoters and the use of PSP – driven virothtrapy of prostate cancer. Biomed Res Int 2013;2013:624632. DOI: 10.1155/2013/624632. PMID: 23484134.
85. Cervantes-Garcia D., Ortiz-López R., Mayek-Pérez N. et al. Oncolytic virotherapy. Ann Hepatol 2008;7(1):34–45. PMID: 18376364.
86. Gonzalez R., Huang W., Finnen R. et. al. Adenovirus E1B 55-kilodalton protein is required for both regulation of mRNA export and efficient entry into the late phase of infection in normal human fibroblasts. J Virol 2006;80:964–74. DOI: 10.1128/JVI.80.2.964-974.2006. PMID: 16378998.
87. Pei-Hsin C., Wechman S.L., McMasters K.M. Oncolytic replication of E1b-deleted adenoviruses. Viruses 2015;7(11):5767–79. DOI: 10.3390/v7112905. PMID: 26561828.
88. Zhou J., Yao Q.M., Li J.L. et al. Synergistic antitumor activity of triple regulated oncolytic adenovirus with VSTM1 and daunorubicin in leukemic cells. Apoptosis 2016;21(10):1179–90. DOI: 10.1007/s10495-016-1276-8. PMID: 27472927.
89. Huang P., Watanabe M., Kaku H. et al. Direct and distant antitumor effects of a telomerase – selective oncolytic adenoviral agent OBP-301 in a mouse prostate cancer model. Cancer Gene Ther 2008;15:315–22. DOI: 10.1038/cgt.2008.3. PMID: 18274558.
90. Daisuke S., Yuji K., Seiji K. et al. Antitumor effects of telomerase-specific replication-selective oncolytic viruses for adenoid cystic carcinoma cell lines. Oncol Reports 2013;30(6):2659–64. DOI: 10.3892/or.2013.2738. PMID: 24065118.
91. Cheng X., Wang W., Xu Q. et al. Genetic modification of oncolytic Newcastle disease virus for cancer therapy. J Virol 2016;90(11):5343–52. DOI: 10.1128/JVI.00136–16. PMID: 27009956.
92. Kojima T., Kuroda S., Yano S. et al. In vivo biological purging for lymph node metastasis of human colorectal cancer by telomerase-specific oncolytic virotherapy. Ann Surg 2010;251(6):1079–86. DOI: 10.1097/SLA. 0b013e3181deb69d. PMID: 20485131.
93. Ruiz A.J., Hadac E.M., Nace R.A. et al. MicroRNA-detargeted mengovirus for oncolytic virotherapy. J Virol 2016;90(8):4078–92. DOI: 10.1128/JVI.02810-15. PMID: 26865716.
94. Lemay C.G., Keller B.A., Edge R.E. et al. Oncolytic Viruses The Best is Yet to Come. Curr Cancer Drug Targets 2018;18(2):109–23. DOI: 10.2174/1568009617666170206111609. PMID: 28176648.
95. Kirn D. Clinical research results with dl1520 (ONYX-015), a replication-selective adenovirus for the treatment of cancer: What have we learned? Gene Ther 2001;8:89–98.
96. Nishiyama Y., Goshima F. Oncolytic virotherapy using replication-competent herpes simplex viruses. Uirusu 2007;57(1):57–65. DOI: 10.2222/jsv.57.57.
97. Markert J.M., Medlock M.D., Rabkin S.D. et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000;7:867–4. DOI: 10.1038/sj.gt.3301205. PMID: 10845725.
98. Freeman A.I., Zakay-Rones Z., Gomori J.M. et al. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther 2006;13:221–8. DOI: 10.1016/j.ymthe.2005.08.016. PMID: 16257582.
99. Сосновцева А.О., Липатова А.В., Гриненко Н.Ф. и др. Чувствительность клеток глиомы C6, несущих полиовирусный рецептор человека, к онколитическим полиовирусам. Бюллетень экспериментальной биологии и медицины 2016;161(6):780–4. [Sosnovtseva A.O., Lipatova A.V., Grinenko N.F. et al. Sensitivity of c6 glioma cells carrying the human poliovirus receptor to oncolytic polioviruses. Bulleten experimentalnoi biologii i medicine = Bulletin of experimental biology and medicini 2016;161(6):780–4. (In Russ.)].
100. Сосновцева А.О., Гриненко Н.Ф., Липатова А.В. и др. Онколитические вирусы в терапии злокачественных глиом. Биомедицинская химия 2016;62(4):376–90. DOI: 10.18097/PBMC20166204376. [Sosnovtceva A.O., Grinenko N.F., Lipatova A.V. Oncolytic viruses for therapy of malignant glioma. Biomedicinskaia Khimiia = Biomedical Khimistry 2016;62(4):376–90 (In Russ.)].
101. Foreman P.M., Friedeman G.K., Cassady К.А. et al. Oncolytic virotherapy for the treatment malignant glioma. Neurotherapeutics 2017;14(2):333–44. DOI: 10.1007/s13311-017-0516-0.
102. Gardeck A.M., Sheehan J., Low W.C. Immune and viral therapies for malignant primary brain tumors. Expert Opin Biol Ther 2017;17(4):457–74. DOI: 10.1080/14712598.2017.1296132. PMID: 28274139.
103. Кешелава В.В., Ляшенко А.А. Патент RU 2379055 от 20.01.2010. Способ лечения онкологических заболеваний. [Keshelava V.V., Lyashenko A.A. Patent RU 2379055 dated January 20, 2010. A method of treating cancer. (In Russ.)].
104. Подольская М.В., Гамарник Т.В. Неоадъювантная иммунотерапия рака молочной железы онколитическим вирусом болезни Ньюкасла. Сибирский онкологический журнал 2009: прил. № 1:156–7. [Podol’skaia M.V., Gamarnik T.V. Neoadjuvant immunotherapy of breast cancer with the oncolytic Newcastle disease virus. Sibirskiy oncologicheskii journal = Siberian journal of Oncology 2009: suppl No 1:156–7. (In Russ.)].
105. Siurala M., Bramante S., Vassilev L. et al. Oncolytic adenovirus and doxorubicin-based chemotherapy results in antitumor activity against soft-tissue sarcoma. Int J Cancer 2015;136:945–54. DOI: 10.1002/ijc.29048. PMID: 24975392.
106. Лоренс Р.М., Робертс М.С. Патент RU 2435586 от 10.01.2011. Лечение рака с применением вирусов фторпиримидинов и камптотецинов. [Lorens R.M., Roberts M.S. Patent RU 2435586 dated 10.01.2011. Cancer therapy with fluoropyrimidine and camptothecin viruses. (In Russ.)].
107. Кleijn A., van den Bossche W., Haefner E.S. et al. The Sequence Delta24-RGD and TMZ Administration in malignant Glioma Affects Role of CD8+T Cell Anti-tumor Activity. Mol Ther Oncolytics 2017;1(5):11–9. DOI: 10.1016/j.omto.2017.02.002. PMID: 28480325.
108. Roberts J.L., Tavallai M., Nourbakhsh A. et al. GRP/Dna K a target for nexavar/stivagra/votrient in the treatment human malignansies, viral infections and bacterial diseases. J Cell Physiol 2015;230:2552–78. DOI: 10.1002/jcp.25014. PMID: 25858032.
109. Berghauser Pont L.M., Balvers R.K., Kloezeman J.J. et al. In vitro screening of clinical drugs identifies sensitizers of oncolytic viral therapy in glioblastoma stem-like cells. Gene Ther 2015;22(13):947–59. DOI: 10.1038/gt.2015.72. PMID: 26196249.
110. Reid T., Galanis E., Abbruzzese J. et al. Intra-arterial administration of a replication-selective adenovirus(dl 1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther 2001;8;1618–26. DOI:10.1038/sj.gt.3301512
111. Pecora A.L., Rizvi N., Cohen G.I. et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 2002;20(9):2251–66. DOI: 10.1200/JCO.2002.08.042. PMID: 11980996.
112. Norman K.L., Lee P.W. K. Reovirus as a novel oncolytic agent. J Clin Invest 2000;105(8):1035–38. DOI:10.1172/JCI9871. PMID: 10772645.
113. Figova K., Hrabeta J., Eckschlager T. Reovirus – possible therapy of cancer. Neopasma 2006;53(6):457–62. PMID: 17167712.
114. Mita A.C. Phase II study of REOLYSIN® in patients with bone and soft tissue sarcomas metastatic to the lung who had been deemed by their physicians to be unresponsive to or untreatable by standard therapies. 15th Annual Connective Tissue Oncology Meeting Miami Beach FL, 2009.
115. Volimann G., Ozduman K., van der Pol A.N. Oncolytic virus therapy for gioblastoma multiforme: Concepts and candidates. Canc J 2012;18(1):69–81. DOI: 10.1097/PPO.0b013e31824671c9. PMID: 22290260.
116. Mahalingam D., Fountzilas C., Moseley J. et al. A phase II study Reolysin(pelareoper) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma. Cancer Chemother Pharmacol 2017;79(4):697–703. DOI: 10.3390/cancers10060160. PMID: 29799479.
117. Babiker H.M., Riaz I.B., Husnain M., Borad M.J. Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma. Oncolytic Virother 2017;9(6):11–8. 10.2147/OV.S100072. PMID: 28224120.
118. Halldén G, Portella G. Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets. Expert Opin Ther Targets 2012;16(10):945–58. DOI: 10.1517/14728222.2012.712962. PMID: 22880939.
119. Gangi A., Zager J.S. The safety talimogene laherparepvec for the treatment of advanced melanoma. Expert Opin Drug Saf 2017;16(2):265–9. DOI: 10.1080/14740338.2017.1274729. PMID: 27989216.
120. Martin C. Oncolytic viruses: treatment and implication for patients with gliomas. Clin J Oncol Nurs 2017;21(2):60–4. DOI: 10.1016/j.nurt.2009.04.011. PMID: 19560745.
121. Msaouel P., Opyrchal M., Dispenzieri A. et al. Clinical trials with oncolytic measles virus: current status and future prospects. Curr Cancer Drug Targets 2018;18(2):177–87. DOI: 10.2174/1568009617666170222125035. PMID: 28228086.
122. Taguchi S., Fukuchara H., Homma Y., Todo T. Current status clinical trials oncolytic virus therapy for urologic cancer. Int J Urol 2017;24(35):342–51. DOI: 10.1111/iju.13325. PMID: 28326624.
123. Вдовиченко Г.В., Петрищенко В.А., Сергеев А.А. и др. Доклинические исследования противоракового лечебного аденовирусного препарата «Канцеролизин». Вопросы вирусологии 2006;6:39–42. [Vdovichenko G.V., Petrishchenko V.A., Sergeev A.A. et al. Preclinical studies of the anticancer adenovirus cancerolysin preparation. Voprosy virusoljgii = Problems of Oncology 2006;51(6):39–42 (In Russ.)].
124. Вдовиченко Г.В., Радаева И.Ф., Сергеев А.А. и др. Создание банков перевиваемой культуры клеток 293 для производства антиракового вирусного лечебного препарата «Канцеролизин». Биотехнология 2006;1:62–7. [Vdovochenko G.V., Radaeva I.F., Sergeev A.A. et al. Development of Banks of a 203-Cell Continuous Culture for Manufacturing the Anti-Tumor Therapeutic Preparation Cancerolysin. Biotechologia = Biotechology 2006;1:62–7. (In Russ.)].
Рецензия
Для цитирования:
Клаан Н.К., Акиньшина Л.П., Пронина Т.А. Онколитические вирусы в терапии злокачественных новообразований. Российский биотерапевтический журнал. 2018;17(4):6-19. https://doi.org/10.17650/1726-9784-2018-17-4-6-19
For citation:
Klaan N.K., Аkin’shina L.P., Pronina T.A. Oncolitical viruses in the therapy of malignant neoplastic diseases. Russian Journal of Biotherapy. 2018;17(4):6-19. (In Russ.) https://doi.org/10.17650/1726-9784-2018-17-4-6-19
Просмотров:
2557
Послать статью по эл. почте 
